Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Last trade$0.8499
Day change+$0.0022 (+0.26%)
Day range$0.788 – $0.905
Volume1,659,079
Market cap$66M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$66.13M
Price / earnings
—
Price / book
2.35×
Price / sales
118.29×
EV / sales
96.72×
EV / EBITDA
-1.38×
Profitability
Earnings per share
-$0.48
Return on assets
-103.45%
Return on equity
-134.06%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.21×
Quick ratio
4.21×
Cash ratio
1.45×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$39.94M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CRDF, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$171K
$104K
$41K
$243K
$120K
$121K
$109K
$151K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$171K
$104K
$41K
$243K
$120K
$121K
$109K
$151K
Selling, general and administrative
$4.36M
$3.8M
$6.13M
$3M
$3.9M
$3.32M
$4.01M
$3.01M
Research and development
$5.03M
$5.92M
$6.77M
$5.08M
$8.2M
$11.58M
$10.48M
$9.71M
Total operating expenses
$9.39M
$9.72M
$12.89M
$8.07M
$12.09M
$14.9M
$14.49M
$12.72M
Operating income
-$9.22M
-$9.62M
-$12.85M
-$7.83M
-$11.97M
-$14.78M
-$14.38M
-$12.57M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$8.86M
-$9.23M
-$12.35M
-$7.22M
-$11.26M
-$13.94M
-$13.43M
-$11.79M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$8.86M
-$9.23M
-$12.35M
-$7.22M
-$11.26M
-$13.94M
-$13.43M
-$11.79M
Net income attributable to common shareholders
-$8.86M
-$9.24M
-$12.35M
-$7.22M
-$11.26M
-$13.95M
-$13.44M
-$11.79M
EBITDA
-$9.13M
-$9.53M
-$12.76M
-$7.74M
-$11.89M
-$14.68M
-$14.29M
-$12.48M
Basic earnings per share
-$0.12
-$0.14
-$0.18
-$0.11
-$0.17
-$0.21
-$0.20
-$0.22
Diluted earnings per share
-$0.12
-$0.14
-$0.18
-$0.11
-$0.17
-$0.21
-$0.20
-$0.22
Recent news
Company coverage with links to the original publishers.
Cardiff Oncology announced that company management will present at the UBS Global Biopharma Conference on November 16-17, 2026. CEO Mani Mohindru will participate in a fireside chat and 1x1 investor meetings. The company is advancing onvansertib, a PLK1 inhibitor in Phase 2 trials for RAS-mutated mCRC treatment.
Cardiff Oncology announced that Dr. Mani Mohindru will present at two upcoming conferences in September 2026, discussing the company's PLK1 inhibitor onvansertib for RAS-mutated metastatic colorectal cancer treatment. The company is advancing its lead asset through Phase 2 trials with positive data previously presented at ASCO.
Cardiff Oncology announced updated Phase 2 CRDF-004 data for onvansertib, a PLK1 inhibitor, will be presented at ASCO 2026 on June 2, 2026, with an investor webcast scheduled for June 3, 2026. The company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab for advancement into a registrational Phase 3 trial for first-line RAS-mutated metastatic colorectal cancer, following positive dose-dependent improvements in response rates and progression-free survival.
Cardiff Oncology announced it will present updated interim data from its Phase 2 CRDF-004 trial evaluating onvansertib, a PLK1 inhibitor, combined with standard chemotherapy and bevacizumab for first-line treatment of RAS-mutated metastatic colorectal cancer at the ASCO 2026 Annual Meeting in Chicago on June 2, 2026.
Cardiff Oncology announced preclinical data showing its PLK1 inhibitor onvansertib enhanced antitumor activity of trastuzumab deruxtecan and reversed resistance in therapy-resistant HER2-low breast cancer models. The findings will be presented at the AACR Annual Meeting in April 2026. Onvansertib is currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer and other cancers.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.